Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Daratumumab and isatuximab show comparable efficacy in newly diagnosed multiple myeloma

Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria
Daratumumab and isatuximab show comparable efficacy in newly diagnosed multiple myeloma ( Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria )
6 Nov 2026

Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
26 Oct 2026

Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Dr Ferdinandos Skoulidis - The University of Texas MD Anderson Cancer Center, Houston, USA
Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC ( Dr Ferdinandos Skoulidis - The University of Texas MD Anderson Cancer Center, Houston, USA )
26 Oct 2026

ESMO 2026: Highlights and analysis

Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2026: Highlights and analysis ( Prof Bishal Gyawali - Queen's University, Kingston, Canada )
26 Oct 2026

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma

Dr Nikhil Khushalani - Moffitt Cancer Center, Tampa, USA
HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma ( Dr Nikhil Khushalani - Moffitt Cancer Center, Tampa, USA )
24 Oct 2026

TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer

Prof Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA
TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer ( Prof Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA )
24 Oct 2026

Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results

Prof Eleftherios Mamounas - AdventHealth Cancer Institute, Orlando, USA
Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results ( Prof Eleftherios Mamounas - AdventHealth Cancer Institute, Orlando, USA )
24 Oct 2026

Building the cancer system of the future in UAE

Dr Stephen Grobmyer - Cleveland Clinic Abu Dhabi - Fatima bint Mubarak Center, Abu Dhabi, United Arab Emirates
Building the cancer system of the future in UAE ( Dr Stephen Grobmyer - Cleveland Clinic Abu Dhabi - Fatima bint Mubarak Center, Abu Dhabi, United Arab Emirates )
9 Oct 2026

Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USA
Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USA )
8 Oct 2026

Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain
Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )
1 Oct 2026

Acyclovir prophylaxis reduces varicella infections in children receiving intensive chemotherapy

Dr Chetan Dhamne - Tata Memorial Hospital in Mumbai, India
Acyclovir prophylaxis reduces varicella infections in children receiving intensive chemotherapy ( Dr Chetan Dhamne - Tata Memorial Hospital in Mumbai, India )
24 Sep 2026

Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC

Dr William William Jr - Oncoclínicas, São Paulo, Brazil
Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC ( Dr William William Jr - Oncoclínicas, São Paulo, Brazil )
18 Sep 2026